Two of the most essential supplies we can offer emerging regions are infrastructure support and easier access to health information
When working globally, the most important thing is the ability to partner with local outposts to implement strategy. A network or alliance is no more advantageous than an independent agency. Instead, what is important is to select an agency partner that is familiar with how to manage local relationships/partnerships. What matters is possessing the flexibility to work with any and all players required to ensure that strategy and branding are understood and implemented.
Ahnal Purohit
Ultimately, the key to global success is having an agency brand champion to manage all local relationships worldwide and ensure consistency across all brand efforts.
When it comes right down to it, at what cost are you willing to sacrifice the critical essentials of strategy, creativity, service, and experience?
With global communications at the crux of the issue, we have to consider the implications of the particular needs of the brand. Many small to midsized specialty brands are heavily reliant on information—and education-based communication. Globally, we are dependent on electronic-based communication, and we have a goal to reinforce and modify consumer behavior.
How we achieve that for these types of specialty brands is quite different, and must be considered when selecting an agency partner.
You convince customers you are better by being better. Of course, understanding value at the customer level for each segment is critical, and there are mechanisms to achieve that understanding. Knowing what is important to them, how they want to be spoken to, and how they want to receive information help us make strategy, concepts, and messaging most relevant to our audience(s).
Accordingly, market research can have significant impact on gaining the necessary customer insight. And while a brand may have its core global offering, modifications may be necessary at the local level to ensure a positive customer experience.
Johnson & Johnson Seeks FDA Approval for Subcutaneous Tremfya Regimen for Ulcerative Colitis
November 22nd 2024Johnson & Johnson has submitted a supplemental Biologics License Application to the FDA for a subcutaneous induction regimen of Tremfya for adults with moderately to severely active ulcerative colitis based on positive Phase III ASTRO trial results.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
Johnson & Johnson Seeks FDA Approval for Subcutaneous Tremfya Regimen for Ulcerative Colitis
November 22nd 2024Johnson & Johnson has submitted a supplemental Biologics License Application to the FDA for a subcutaneous induction regimen of Tremfya for adults with moderately to severely active ulcerative colitis based on positive Phase III ASTRO trial results.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
2 Commerce Drive
Cranbury, NJ 08512